106 – Deep Dive into Regulatory Affairs (S8E1)

We've got a really fascinating collection of
stuff here. Like we're talking everything from
the nitty gritty of how drugs are made at the
molecular level, you know, medicinal chemistry
and all that, all the way to the big picture
of how pharmaceutical companies actually get
those drugs out there, like the whole development
process. And today we're going deep, really deep
into a part of that process that most people
don't even think about, but that's absolutely
crucial. regulatory affairs yeah that's right
it's kind of like you know everyone gets excited
about the big scientific breakthroughs right
like discovering a new drug or a new therapy
right but there's this whole system in place
like a framework that make sure those discoveries
actually become something that can help people
safely and effectively. So that's what we're
going to untangle today using all this great
material you've pulled together on medicinal
chemistry, preclinical stuff, clinical trials,
all of it. Exactly. And our mission here, if
you will, is to first off, like really get clear
on who the major players are in this world. What
are the agencies? What are the guidelines they
set? All that good stuff. Then we want to understand,
like, what do these regulatory professionals,
these experts actually do. What's their role?
And finally, we'll even try to peek into the
future a little bit. Like, what's coming down
the pike in this field? You know, as always,
we want to make this stuff clear, engaging, and
most importantly, relevant for you. Absolutely.
And I think it's a perfect time for a deep dive
like this because the regulatory landscape is
constantly shifting. Like one of the biggest
shifts we're seeing right now is this huge influx
of like totally new types of therapies. We're
talking gene therapies, personalized medicine,
things that were barely on the radar even a few
years ago. Yeah, for sure. OK, so let's get started.
You mentioned players, right? Like who are the
big names, the agencies we need to know about
in this regulatory world? So the biggest name,
at least here in the U .S., is the FDA, you know,
the Food and Drug Administration. Right. Everyone's
heard of the FDA. But like, what's their actual
authority based on? Like, legally speaking, how
do they get to tell drug companies what to do?
That's a great question. So their power basically
comes from this really specific legal framework.
Specifically, we're talking Title 21 of the Code
of Federal Regulations. OK, Title 21. Got it.
Yeah. And within that, there's this one section,
Part 312, that's super important. It's basically
the rule book for what's called an IND application,
which stands for Investigational New Drug. IND.
OK. Right. So think of an IND application as
your permission slip to start testing a new drug
on humans. So before you can even start a clinical
trial, you have to go to the FDA hat in hand
with this IND and say, hey, Can we do this? Exactly.
It's like the FDA's first big checkpoint. They
want to make sure everything's safe and legit
before any human subjects get involved. That
makes sense. So in the US, it's the FDA and this
Title 21 Part 312 thing. What about over in Europe?
Is there a European equivalent of the FDA? Oh,
yeah, definitely. In the European Union, they've
got the EMA, the European Medicines Agency, and
their job is basically the same. Make sure all
the medicines developed for use in the EU are
safe effective high quality You know the drill
right gotta have those standards exactly so any
company that wants their drug to be available
in Europe They got to know the EMA inside and
out gotcha So we've got the FDA in the US, the
EMA in Europe. Now you mentioned another organization
earlier, the ICH. What does that stand for again?
International Council for Harmonization. And
it's kind of unique because unlike the FDA or
EMA, the ICH doesn't actually have any legal
authority. They don't set any official regulations.
Okay, interesting. So if they don't have that
kind of power, What do they actually do? Like,
why are they important? So what the ICH does
is bring together these regulatory authorities
like the FDA and the IMEA and the pharmaceutical
industry from like all the major regions, you
know, U .S., Europe, Japan, and they all sit
down together and try to agree on basically the
best scientific and technical practices for drug
development, like what kind of data should be
collected, how should clinical trials be designed,
all that stuff. So they're trying to create like
a global standard for drug development. Exactly.
And even though their guidelines aren't legally
binding, they have a huge influence. Like if
the ICH says, hey, this is the best way to do
this, then you can bet that regulators all over
the world are going to expect to see that reflected
in a drug application. It's like if you want
to play ball glo - globally, you got to follow
the ICH playbook. Yeah, pretty much. And it makes
sense, right? Like, the goal is to develop drugs
that can help people all over the world. So it's
helpful to have some kind of global consensus
on how to do that safely and effectively. Definitely.
Now, going back to the FDA and the EMA, you talked
about how they're kind of like gatekeepers, right?
Like, they have to give the thumbs up before
a drug can be tested in humans or approved for
sale. Right. So let's dig into that a bit more.
Let's start with the FDA. Like, what exactly
do they do to make sure that a drug is safe enough
to be tested in humans. Okay, so remember that
IND application we talked about? Yeah, the permission
slip to start human trials. Right. So that's
where it all starts. The drug developer basically
has to lay out their entire plan for testing
the drug in humans, and this plan has to be super
detailed. It includes everything from the drug's
chemical structure to how it's made, results
from any pre -clinical studies, and the exact
protocol for the proposed clinical trials. Okay,
so they really have to show their work, so to
speak. Oh, yeah, absolutely. And then the FDA
takes all that information and goes over it with
a fine -tooth comb. They're looking for anything
that might raise a red flag about the drug's
safety. Like what kind of red flags? Well, for
example, they might be looking at the results
from the preclinical studies and say, hmm, this
drug caused some weird side effects in animals.
We need more data before we're comfortable letting
you test it in humans. Right. So they're really
acting as the protectors of human subjects. Exactly.
It's a huge responsibility. And one of the things
your sources really emphasize is that Understanding
these regulations, like really understanding
them is crucial from the very beginning of drug
development. Makes sense. Like you can't just
wing it and hope for the best when you're dealing
with people's health. So it's all about doing
your homework and making sure everything is up
to snuff before you even go to the FDA. Exactly.
And the same goes for the EMA. They have their
own set of requirements, which may be similar,
but not necessarily identical to the FDA's. So
if you're a drug company and you want to market
your drug in both the US and Europe, you have
to be aware of both sets of regulations. Gotcha.
Now, let's circle back to the ICH. You said earlier
that they don't have any real legal power, but
that their guidelines are still super influential.
How does that work in practice? Why do companies
actually pay attention to what they say? So the
thing about the ICH is that it represents this
kind of like global consensus like all the major
Regulatory agencies and pharmaceutical companies
have agreed that yeah, these are the best practices
for drug development So even though they're not
legally binding it's in everyone's best interest
to follow them because if you don't Well, let's
say you're a drug company and you decide to do
things your own way, completely ignoring the
ICH guidelines. Now, you might be able to get
your drug approved in one country, but it's going
to be a lot harder to get it approved elsewhere.
Because other countries are going to be like,
hey, why didn't you follow the standard playbook?
Exactly. So it's really about streamlining the
process. Like if everyone's on the same page
about what data needs to be collected and how
things should be done, then it makes it easier
for drugs to be developed and approved globally.
And that ultimately means that patients get access
to new treatments faster. Precisely. So while
the ICH might not have the same kind of legal
clout as the FDA or EMEA, it plays a super important
role in shaping the global drug development landscape.
Okay. That makes a lot of sense. Now, all this
talk about regulations and guidelines, it makes
me wonder, like, who actually deals with all
this stuff? Like, within a drug company, who's
responsible for navigating this whole regulatory
maze? Ah, that's where regulatory affairs professionals
come in. They are the experts, the people who
live in... They're like the regulatory whisperers.
Yeah, kind of. They have to have a deep understanding
of all the relevant regulations and guidelines,
and they're responsible for making sure that
every step of the drug development process is
done by the book. So it's not just about... Like
filling out paperwork at the end, right? No,
not at all. They're involved from the very beginning.
Like even in those early preclinical studies,
they're working with the scientists to make sure
that the studies are designed in a way that meets
regulatory requirements. So they're like the
bridge between the scientists who are developing
the drug and the regulatory agencies who are
overseeing the whole process. Exactly. And one
of the things that your sources emphasize is
that This communication between the drug developers
and the regulatory agencies is ongoing. It's
not just a one time thing. So it's a constant
back and forth. Exactly. And that's where the
regulatory affairs professionals really shine.
They're the ones who keep that communication
flowing and make sure that everyone is on the
same page. So they're kind of like the diplomats
of the drug development world. Yeah. I like that
analogy because they really do have to be skilled
communicators and negotiators. They have to be
able to explain complex science. concepts to
regulators who might not have a scientific background
and they also have to be able to advocate for
the company's position while still staying within
the bounds of the regulations. It sounds like
a pretty demanding job. It definitely can be
but it's also incredibly important because at
the end of the day it's the regulatory affairs
professionals who help make sure that new drugs
are developed safely and effectively and that
they actually reach the patients who need them.
Right. And speaking of patient safety, that's
obviously a huge concern with any new drug. Like
how do regulatory agencies help ensure that the
drugs that ultimately get approved are actually
safe for people to take? So that's where all
those meticulous review processes come in. Like
when the FDA reviews an IND application or when
the EMA reviews a marketing authorization application,
one of their primary focuses is on safety. So
they're looking for any potential red flags,
anything that suggests the drug might be harmful.
Exactly. They look at the preclinical data. They
look at the clinical trial data. They look at
everything. And they're guided by all those regulations
and guidelines we talked about earlier, like
the ones from the ICH. And they're constantly
monitoring the safety data even after a drug
is approved. If there are reports of unexpected
side effects, they can take action. So it's not
just a one -time check. They're keeping an eye
on things long -term. Exactly. And one of the
things that your sources highlight is this concept
of risk -benefit analysis. Like, no drug is completely
risk -free, but the goal is to make sure that
the potential benefits of a drug outweigh the
potential risks. Right. It's all about finding
that balance. And you mentioned an example earlier,
a really tragic one, where a young man died during
a gene therapy trial. That really highlights
the importance of having these robust safety
checks in place. Yeah, absolutely. It's a stark
reminder that things can go wrong and that we
need to be incredibly careful when we're developing
new treatments, especially when we're dealing
with cutting edge technologies like gene therapy.
Right. Now, beyond safety, another important
consideration is consistency. Like, how do we
know that a drug that's been approved is going
to be made the same way every time so that each
dose is going to be effective and safe? That's
a great question. And that's where good manufacturing
practices or GMPs come in. These are basically
a set of regulations that dictate how drugs should
be manufactured. So it's like a recipe book for
drug making. Yeah, kind of. They cover everything
from the quality of the raw materials to the
cleanliness of the facilities to the training
of the personnel. And the goal is to make sure
that every batch of a drug is made to the same
high standard. So no matter where in the world
you buy a particular drug, you can be confident
that it's going to be the same. Exactly. And
this is another area where regulatory affairs
professionals play a key role. They work with
the manufacturing teams to make sure that all
the GMP requirements are being met. It sounds
like they're involved in pretty much every aspect
of drug development. They really are. It's a
truly multifaceted role. OK, so we've covered
a lot of ground here. We've talked about the
major regulatory agencies, the guidelines they
set, the role of regulatory affairs professionals,
the importance of safety and consistency. I'm
curious, like, what's next for this field? What
are some of the big trends on the horizon? So,
one of the biggest trends right now is the increasing
use of artificial intelligence, or AI, in drug
development. And this is having a huge impact
on regulatory affairs. Like how so? Well, for
one thing, AI is being used to analyze massive
amounts of data, which can help identify potential
safety issues much earlier in the development
process. And it's also being used to personalize
treatments, which raises a whole new set of regulatory
challenges. Right, because if every patient's
getting a slightly different treatment, how do
you regulate that? Exactly. It's a whole new
ballgame. And then there's the issue of data
privacy, which is obviously a huge concern with
AI. So regulatory agencies are having to adapt
and develop new guidelines to address all these
challenges. So it sounds like regulatory affairs
professionals are going to need to be pretty
tech savvy moving forward. Absolutely. They need
to be able to understand how AI is being used
and what the implications are for drug development
and regulation. And they also need to be able
to communicate effectively with the AI experts.
So it's like they're becoming even more multifaceted.
Yeah, pretty much. It's a really exciting time
to be in this field because it's constantly evolving.
Definitely. And I think that's a great place
to wrap up our deep dive. We've covered a lot
of ground, but hopefully it's given our listeners
a better understanding of this really important,
but often overlooked, aspect of drug development.
So to end on a thought -provoking note, I'm curious,
what do you see as the biggest challenge facing
drug regulation in the coming decade? What are
the big questions that regulators are going to
have to grapple with? Hmm. That's a tough one.
I think one of the biggest challenges is going
to be balancing the need to foster innovation
with the need to ensure patient safety. Like,
we don't want to stifle the development of new
treatments, but we also don't want to put patients
at risk. And with all these new technologies
coming online, like gene editing and personalized
medicine, it's going to be a real balancing act.
Yeah, that makes sense. And I think that's a
question that's going to be relevant for all
of us, not just those working in drug development,
because ultimately we all want access to safe
and effective treatments. Exactly. And that's
why the work that regulatory affairs professionals
do is so vital. Absolutely. Well, thank you so
much for taking us on this deep dive. It's been
really illuminating. My pleasure. Always happy
to talk about this stuff. And to our listeners,
thanks for joining us. We'll see you next time
for another deep dive.